CAMBRIDGE, Mass.--(BUSINESS WIRE)--MPM Capital (MPM), one of the world’s prominent biotech investment firms, has announced the addition of Detlev Biniszkiewicz, Ph.D. to its venture investment team as a Managing Director and Investment Committee member.
“We are delighted to announce the addition of Detlev to our investment committee,” said Ansbert Gadicke, M.D., MPM Managing Director. “Detlev’s leadership experience combined with the depth of his scientific background has added significant value to MPM and to our portfolio companies. His dedication and excellence as an entrepreneur have been invaluable to our goal of discovering the latest breakthrough science and building companies to deliver lifesaving therapies. We are pleased to recognize Detlev’s hard work and unwavering commitment to MPM’s mission.”
Detlev Biniszkiewicz, Ph.D. joined MPM in 2018 as an Executive Partner. Since joining MPM, Detlev has been instrumental in launching several MPM portfolio companies, including NextPoint Therapeutics. Detlev currently serves on the board of iTeos Therapeutics (NASDAQ: ITOS) and previously served on the board of Maverick Therapeutics until its acquisition by Takeda earlier this year.
MPM Capital is a prominent biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its seasoned team and deep experience in scientific research, clinical development, and company-building, MPM strives to power novel medical breakthroughs that transform patients’ lives. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. For more information visit www.mpmcapital.com.